Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome

Robert H. Howland, A. John Rush, Stephen R. Wisniewski, Madhukar H. Trivedi, Diane Warden, Maurizio Fava, Lori L. Davis, G. K. Balasubramani, Patrick J. McGrath, Susan R. Berman

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Background: Depressed patients often present with comorbid anxiety and/or substance use disorder. This report compares the four groups defined by the disorders (anxiety disorder, substance use disorder, both, and neither) in terms of baseline clinical and sociodemographic features, and in terms of outcomes following treatment with citalopram (a selective serotonin reuptake inhibitor). Methods: The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial enrolled 2838 outpatients with non-psychotic major depressive disorder (MDD) from 18 primary and 23 psychiatric care clinics. Clinical and sociodemographic features were assessed at baseline. These baseline features and the treatment outcomes following treatment with citalopram were compared among the four groups. Results: Participants with non-psychotic MDD and comorbid anxiety and/or substance use disorder showed several distinctive baseline sociodemographic and clinical features. They also showed greater depression severity; length of illness; likelihood of anxious, atypical or melancholic features; more intolerance/attrition; and worse remission/response outcomes with treatment. Participants with either anxiety or substance use disorder showed outcomes generally intermediate between those with both and those with neither. Conclusions: Comorbid anxiety and/or substance use disorder are clinically identifiable, and their presence may define distinct MDD subgroups that have more problems and worse pharmacological treatment outcomes. They may benefit from more aggressive, multi-faceted treatment and psychosocial rehabilitation targeted at reducing their psychological comorbidity and functional impairment.

Original languageEnglish (US)
Pages (from-to)248-260
Number of pages13
JournalDrug and Alcohol Dependence
Volume99
Issue number1-3
DOIs
StatePublished - Jan 1 2009

Fingerprint

Citalopram
Substance-Related Disorders
Outpatients
Anxiety
Depression
Major Depressive Disorder
Serotonin Uptake Inhibitors
Patient rehabilitation
Anxiety Disorders
Psychiatry
Comorbidity
Therapeutics
Pharmacology
Psychology

Keywords

  • Alcohol abuse
  • Antidepressant treatment
  • Anxiety
  • Anxiety disorders
  • Comorbidity
  • Depression
  • Drug abuse
  • Major depression
  • Substance use disorders
  • Treatment outcome

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Toxicology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Concurrent anxiety and substance use disorders among outpatients with major depression : Clinical features and effect on treatment outcome. / Howland, Robert H.; John Rush, A.; Wisniewski, Stephen R.; Trivedi, Madhukar H.; Warden, Diane; Fava, Maurizio; Davis, Lori L.; Balasubramani, G. K.; McGrath, Patrick J.; Berman, Susan R.

In: Drug and Alcohol Dependence, Vol. 99, No. 1-3, 01.01.2009, p. 248-260.

Research output: Contribution to journalArticle

Howland, RH, John Rush, A, Wisniewski, SR, Trivedi, MH, Warden, D, Fava, M, Davis, LL, Balasubramani, GK, McGrath, PJ & Berman, SR 2009, 'Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome', Drug and Alcohol Dependence, vol. 99, no. 1-3, pp. 248-260. https://doi.org/10.1016/j.drugalcdep.2008.08.010
Howland, Robert H. ; John Rush, A. ; Wisniewski, Stephen R. ; Trivedi, Madhukar H. ; Warden, Diane ; Fava, Maurizio ; Davis, Lori L. ; Balasubramani, G. K. ; McGrath, Patrick J. ; Berman, Susan R. / Concurrent anxiety and substance use disorders among outpatients with major depression : Clinical features and effect on treatment outcome. In: Drug and Alcohol Dependence. 2009 ; Vol. 99, No. 1-3. pp. 248-260.
@article{c367262e891f4e208fcbcffff786899e,
title = "Concurrent anxiety and substance use disorders among outpatients with major depression: Clinical features and effect on treatment outcome",
abstract = "Background: Depressed patients often present with comorbid anxiety and/or substance use disorder. This report compares the four groups defined by the disorders (anxiety disorder, substance use disorder, both, and neither) in terms of baseline clinical and sociodemographic features, and in terms of outcomes following treatment with citalopram (a selective serotonin reuptake inhibitor). Methods: The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial enrolled 2838 outpatients with non-psychotic major depressive disorder (MDD) from 18 primary and 23 psychiatric care clinics. Clinical and sociodemographic features were assessed at baseline. These baseline features and the treatment outcomes following treatment with citalopram were compared among the four groups. Results: Participants with non-psychotic MDD and comorbid anxiety and/or substance use disorder showed several distinctive baseline sociodemographic and clinical features. They also showed greater depression severity; length of illness; likelihood of anxious, atypical or melancholic features; more intolerance/attrition; and worse remission/response outcomes with treatment. Participants with either anxiety or substance use disorder showed outcomes generally intermediate between those with both and those with neither. Conclusions: Comorbid anxiety and/or substance use disorder are clinically identifiable, and their presence may define distinct MDD subgroups that have more problems and worse pharmacological treatment outcomes. They may benefit from more aggressive, multi-faceted treatment and psychosocial rehabilitation targeted at reducing their psychological comorbidity and functional impairment.",
keywords = "Alcohol abuse, Antidepressant treatment, Anxiety, Anxiety disorders, Comorbidity, Depression, Drug abuse, Major depression, Substance use disorders, Treatment outcome",
author = "Howland, {Robert H.} and {John Rush}, A. and Wisniewski, {Stephen R.} and Trivedi, {Madhukar H.} and Diane Warden and Maurizio Fava and Davis, {Lori L.} and Balasubramani, {G. K.} and McGrath, {Patrick J.} and Berman, {Susan R.}",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.drugalcdep.2008.08.010",
language = "English (US)",
volume = "99",
pages = "248--260",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-3",

}

TY - JOUR

T1 - Concurrent anxiety and substance use disorders among outpatients with major depression

T2 - Clinical features and effect on treatment outcome

AU - Howland, Robert H.

AU - John Rush, A.

AU - Wisniewski, Stephen R.

AU - Trivedi, Madhukar H.

AU - Warden, Diane

AU - Fava, Maurizio

AU - Davis, Lori L.

AU - Balasubramani, G. K.

AU - McGrath, Patrick J.

AU - Berman, Susan R.

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: Depressed patients often present with comorbid anxiety and/or substance use disorder. This report compares the four groups defined by the disorders (anxiety disorder, substance use disorder, both, and neither) in terms of baseline clinical and sociodemographic features, and in terms of outcomes following treatment with citalopram (a selective serotonin reuptake inhibitor). Methods: The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial enrolled 2838 outpatients with non-psychotic major depressive disorder (MDD) from 18 primary and 23 psychiatric care clinics. Clinical and sociodemographic features were assessed at baseline. These baseline features and the treatment outcomes following treatment with citalopram were compared among the four groups. Results: Participants with non-psychotic MDD and comorbid anxiety and/or substance use disorder showed several distinctive baseline sociodemographic and clinical features. They also showed greater depression severity; length of illness; likelihood of anxious, atypical or melancholic features; more intolerance/attrition; and worse remission/response outcomes with treatment. Participants with either anxiety or substance use disorder showed outcomes generally intermediate between those with both and those with neither. Conclusions: Comorbid anxiety and/or substance use disorder are clinically identifiable, and their presence may define distinct MDD subgroups that have more problems and worse pharmacological treatment outcomes. They may benefit from more aggressive, multi-faceted treatment and psychosocial rehabilitation targeted at reducing their psychological comorbidity and functional impairment.

AB - Background: Depressed patients often present with comorbid anxiety and/or substance use disorder. This report compares the four groups defined by the disorders (anxiety disorder, substance use disorder, both, and neither) in terms of baseline clinical and sociodemographic features, and in terms of outcomes following treatment with citalopram (a selective serotonin reuptake inhibitor). Methods: The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial enrolled 2838 outpatients with non-psychotic major depressive disorder (MDD) from 18 primary and 23 psychiatric care clinics. Clinical and sociodemographic features were assessed at baseline. These baseline features and the treatment outcomes following treatment with citalopram were compared among the four groups. Results: Participants with non-psychotic MDD and comorbid anxiety and/or substance use disorder showed several distinctive baseline sociodemographic and clinical features. They also showed greater depression severity; length of illness; likelihood of anxious, atypical or melancholic features; more intolerance/attrition; and worse remission/response outcomes with treatment. Participants with either anxiety or substance use disorder showed outcomes generally intermediate between those with both and those with neither. Conclusions: Comorbid anxiety and/or substance use disorder are clinically identifiable, and their presence may define distinct MDD subgroups that have more problems and worse pharmacological treatment outcomes. They may benefit from more aggressive, multi-faceted treatment and psychosocial rehabilitation targeted at reducing their psychological comorbidity and functional impairment.

KW - Alcohol abuse

KW - Antidepressant treatment

KW - Anxiety

KW - Anxiety disorders

KW - Comorbidity

KW - Depression

KW - Drug abuse

KW - Major depression

KW - Substance use disorders

KW - Treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=57049107321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049107321&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2008.08.010

DO - 10.1016/j.drugalcdep.2008.08.010

M3 - Article

C2 - 18986774

AN - SCOPUS:57049107321

VL - 99

SP - 248

EP - 260

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-3

ER -